Skip to content
DataLookout
Menu

NCT02194738

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 1377 versions: 21 with changes below, 29 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites revised (1660)
  2. Minor Study sites revised (1660)
  3. Minor Study sites revised (1660)
  4. Minor Final enrollment: 7458 participants (planned 8300)
    • Primary completion date changed from estimate of Sep 28, 2026 to Dec 3, 2025
    • Study completion pushed from Sep 28, 2026 to Sep 21, 2027
    • Site details revised at 135 of 1660 sites
  5. Minor Study sites revised (1660)v1373
Show 16 earlier versionsHide 16 earlier versions
  1. Minor Study sites: 1661 to 1660v1371
  2. Minor Study sites revised (1661)v1370
  3. Minor Study sites revised (1661)v1369
  4. Minor Study sites revised (1661)v1368
  5. Minor Study sites revised (1661)v1367
  6. Minor Study sites revised (1661)v1366
  7. Minor Study sites revised (1661)v1365
  8. Minor Study sites revised (1661)v1364
  9. Minor Study sites: 1662 to 1661v1363
  10. Minor Study sites revised (1662)v1362
  11. Minor Study sites revised (1662)v1360
  12. Minor Study sites: 1663 to 1662v1359
  13. Minor Study sites revised (1663)v1358
  14. Minor Study sites revised (1663)v1357
  15. Minor Study sites revised (1663)v1348
  16. Study Status, Contacts/Locationsv1337
  • Minor: routine updates

Endpoints

Primary

Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105
Timeframe: Up to 4 years
Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis
Timeframe: Up to 4 years

Secondary (2)

Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK
Agreement of local genotyping methods (direct sequencing of EGFR, ALK fluorescence in situ hybridization [FISH]) with central Clinical Laboratory Improvement Amendments genotyping

Arms and interventions

A081105 Arm A (blinded erlotinib hydrochloride)Experimental

Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)

A081105 Arm B (placebo)Placebo comparator

Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)

A081105 Arm C (unblinded erlotinib hydrochloride)Experimental

Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

A081105 Arm D (observation)Active comparator

Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.

A081801 Arm A (platinum doublet, observation)Active comparator

INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then undergo observation.

A081801 Arm B (platinum doublet, sequential pembrolizumab)Experimental

INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 17 cycles in the absence of disease progression or unacceptable toxicity.

A081801 Arm C (platinum doublet, combination pembrolizumab)Experimental

INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice and pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 13 cycles in the absence of disease progression or unacceptable toxicity.

E4512 Arm A (crizotinib)Experimental

Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

E4512 Arm B (observation)Active comparator

Patients undergo observation.

EA5142 Arm I (nivolumab)Experimental

Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET/CT throughout the trial and blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated.

EA5142 Arm II (observation)Active comparator

Patients are followed serially with CT and/or PET/CT imaging for up to 1 year and then during follow-up. Patients also undergo blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.

Procedures: Biospecimen Collection, Computed Tomography, Echocardiography Test, Positron Emission Tomography

Drugs: Carboplatin, Cisplatin, Crizotinib, Erlotinib, Gemcitabine Hydrochloride, Paclitaxel, Pemetrexed, Pemetrexed Disodium

Other: Clinical Observation, Cytology Specimen Collection Procedure, Placebo Administration

Biologicals: Nivolumab, Pembrolizumab

Sites

1,660 sites in 3 countries

United States 1655, Puerto Rico 4, Guam 1